Moxifloxacin and Hepatitis - a phase IV clinical study of FDA data

Summary:

Hepatitis is reported as a side effect among people who take Moxifloxacin (moxifloxacin), especially for people who are female, 50-59 old, have been taking the drug for < 1 month also take Claritin, and have Tuberculosis.

The phase IV clinical study analyzes which people have Hepatitis when taking Moxifloxacin. It is created by eHealthMe based on reports of 12,960 people who have side effects when taking Moxifloxacin from the FDA, and is updated regularly.

What is Moxifloxacin?

Moxifloxacin has active ingredients of moxifloxacin. eHealthMe is studying from 12,980 Moxifloxacin users. Check the latest studies of Moxifloxacin.

What is Hepatitis?

Hepatitis (inflammation of the liver) is found to be associated with 1,472 drugs and 1,522 conditions by eHealthMe. Check the latest studies of Hepatitis.

On Jul, 08, 2026

12,960 people reported to have side effects when taking Moxifloxacin.
Among them, 73 people (0.56%) have Hepatitis.

Among these 73 people:

How long have people been on Moxifloxacin when they have Hepatitis? *

What is the gender of people who have Hepatitis when taking Moxifloxacin? *

female: 72.73 %
male: 27.27 %

What is the age of people who have Hepatitis when taking Moxifloxacin? *

What are other drugs people take besides Moxifloxacin? *

What are other side effects people have besides Hepatitis? *

Acute Kidney Failure: 20 people, 27.40%
Dyspnea (difficult or laboured breathing): 19 people, 26.03%
Renal Disorder (kidney disease): 19 people, 26.03%
Vasodilatation (widening of blood vessels resulting from relaxation of smooth muscle cells within the vessel walls): 18 people, 24.66%
Pleural Effusion (water on the lungs): 18 people, 24.66%
Atelectasis (partial or complete collapse of the lung): 18 people, 24.66%
Supraventricular Extrasystoles (premature electrical impulse in the heart, generated above the level of the ventricle): 18 people, 24.66%
Gallbladder Disorder: 18 people, 24.66%
Gallstones (stone formation by bile component): 18 people, 24.66%
Nausea And Vomiting: 16 people, 21.92%

What are the existing conditions these people have? *

Tuberculosis (a bacterial infection by mycobacterium tuberculosis): 19 people, 26.03%
Disseminated Tuberculosis: 7 people, 9.59%
Interstitial Lung Disease: 6 people, 8.22%
Pulmonary Tuberculosis (lungs tuberculosis): 6 people, 8.22%
Pneumonia Pneumococcal (pneumococcal pneumonia is a common but serious infection and inflammation of the lungs): 6 people, 8.22%
Tuberculosis Of Central Nervous System (a bacterial infection of brain and spinal cord by mycobacterium tuberculosis): 5 people, 6.85%
Pneumonia: 3 people, 4.11%
Gastritis (inflammation of stomach): 3 people, 4.11%
Meningitis Bacterial (bacterial inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges): 2 people, 2.74%
Immunodeficiency Disorders: 2 people, 2.74%

* Approximation only. Some reports may have incomplete information.

Do you take Moxifloxacin and have Hepatitis?

- Check whether Hepatitis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Moxifloxacin:

Moxifloxacin (12,980 reports)

Hepatitis treatments and more:

Hepatitis (31,197 reports)

Browse all side effects of Moxifloxacin:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hepatitis:

Hepatitis (1,472 drugs)

Browse all the conditions that are associated with Hepatitis:

Hepatitis (1,522 conditions)

Related publications that referenced our studies

Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .
Mati?, K., & Pele?, A. M. , "Drug-induced toxic hepatitis associated with the combination of quetiapine and fluphenazine: A case report", The European Journal of Psychiatry, 2018 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on moxifloxacin (the active ingredients of Moxifloxacin) and Moxifloxacin (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.